Mobile
Recherche simple
Recherche avancée
Recherche multicritère
Qui sommes-nous ?
Connexion
Inscription
French
English
Kusajili – Centralise les essais cliniques mondiaux
Résultat
de votre recherche par promoteur : Chiesi Farmaceutici S.p.A
Femme et Homme Max 99 ans
Chiesi Farmaceutici S.p.A
MAJ Il y a 4 ans
Double blind, double dummy, multinational, multicenter, parallel-group design clinical trial of superiority of CHF 1535 1 puff in a b.i.d regimen administered via an HFA-propellant-pMDI versus a double equivalent dose of Beclomethasone Dipropionate in b.i.d regimen administered via an CFC-propellant–pMDI in a 12 week treatment period of mild to moderate persistent asthma in adults patients
To demonstrate the clinical superiority in terms of pulmonary function of CHF 1535 (formoterol and beclomethasone fixed combination) vs. a double dose of beclomethasone alone in the 12-week treatment ...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations
Femme et Homme Max 99 ans
Chiesi Farmaceutici S.p.A
MAJ Il y a 4 ans
Study to assess the inhalation profile obtained by acoustic monitoring in COPD patients using the inhaler NEXThaler® Studio per valutare il profilo inalatorio attraverso un monitoraggio acustico in pazienti con COPD utilizzando l'inalatore NEXThaler®
The primary objective of this study is to assess the inspiration profile through the NEXThaler® device in COPD patients with varying degrees of airflow limitation as per GOLD 2013 (updated) spirometri...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Chiesi Farmaceutici S.p.A
MAJ Il y a 4 ans
A study to look at the bronchodilator effect of two strengths of a fixed combination administered at different doses by inhalation via NEXThaler to asthmatic patients
To demonstrate the non-inferiority in terms of acute bronchodilator effect (FEV1 AUC0-12h) between a single dose of CHF 1535 NEXThaler® 200 + 6 µg and a single dose of CHF 1535 NEXThaler® 100 + 6 µg a...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Chiesi Farmaceutici S.p.A
MAJ Il y a 4 ans
A study in Chronic Obstructive Pulmonary Disease patients to evaluate the efficacy and safety of 4 different doses of a new medicine, CHF 6001 given for 6 months
The primary objective of this trial will be to investigate the dose-response relationship of 4 doses of CHF 6001 DPI with respect to predose FEV1 after 12 weeks of treatment and to identify the optima...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations
Femme et Homme Max 99 ans
Chiesi Farmaceutici S.p.A
MAJ Il y a 4 ans
A research study to evaluate the effect of a new medicine (glycopyrrolate) administered on top of a licensed medicine (Qvar) in patients with uncontrolled asthma
To evaluate the superiority of CHF 5259 pMDI (glycopyrrolate bromide) (50 μg total daily dose) versus placebo in terms of FEV1 AUC0-12h normalised by time on Day 42.
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Chiesi Farmaceutici S.p.A
MAJ Il y a 4 ans
Study On Safety And Efficacy Of A New Drug CHF 5633 To Treat Respiratory Failure In Premature Babies
The primary aim of this study is to evaluate the safety and tolerability of intratracheal administration of two different single doses of CHF 5633 in preterm neonates with RDS, in terms of adverse eve...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Chiesi Farmaceutici S.p.A
MAJ Il y a 4 ans
IN-VIVO DEPOSITION MEASUREMENT OF BECLOMETASONE AND FORMOTEROL AFTER INHALATION OF A SINGLE DOSE OF THE COMBINATION BDP PLUS FORMOTEROL NEXT (TM) DPI IN HEALTHY VOLUNTEERS, ASTHMATIC AND COPD PATIENTS
Primary: To evaluate the amount of drug deposited within the lungs (intrapulmonary drug deposition relative to the nominal dose, DL, N) in healthy volunteers, asthmatic and COPD patients.
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Chiesi Farmaceutici S.p.A
MAJ Il y a 4 ans
A SINGLE CENTRE DOUBLE-BLIND, RANDOMISED 3 PERIOD CROSS OVER STUDY TO COMPARE SAFETY ASSESSED BY KNEMOMETRY AND URINARY CORTISOL MEASUREMENTS OF BECLOMETHASONE DIPROPIONATE HFA pMDI 100 AND 200 µg B.I.D. USING AEROCHAMBER PLUS™ SPACING DEVICE AND BECLOMETHASONE DIPROPIONATE HFA pMDI 200 µg B.I.D. USING THE VOLUMATIC™ SPACING DEVICE IN CHILDREN WITH MILD ASTHMA DURING A 2–WEEK TREATMENT PERIOD
The primary objective of the study is to compare lower leg growth rate (LLGR), measured by knemometry, over a 2-week treatment period with BDP HFA pMDI 200 µg b.i.d. using AeroChamber Plus™ spacing de...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Précédent
1
2
3
4
5
6